Studies

Could psilocybin help slow aging?  A fascinating new study suggests it may extend the lifespan of human skin and lung cells by over 50% — with effects on telomere maintenance, oxidative stress, and DNA repair. While more human research is needed, the findings open the door to thinking differently about aging and wellness.

A preclinical study, published in the journal "Pharmacological Research" and led by the Universities of Padua and Milan, shows that chronic administration of very low, non-psychedelic doses of psilocybin produces metabolic benefits in models of obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MASLD).

A new study announced Wednesday shows that psilocybin -- the active compound in "magic mushrooms" -- and mindfulness training can together ease depression and burnout among healthcare workers.

In 2016 psychiatrist Benjamin Kelmendi was treating two patients with severe, treatment-resistant obsessive-compulsive disorder (OCD) at a Connecticut mental health center when the patients abruptly disappeared, abandoning their treatment plans without a word of explanation.

Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistance. Psilocybin-assisted therapy (PAT) shows promise in reducing depressive symptoms, but long-term effects are unknown. We aimed to determine the long-term safety and efficacy of PAT for MDD over a five-year follow-up period.

ajor depressive disorder (MDD) is a significant public health concern, and current treatments often have limitations in effectiveness and adherence. Psilocybin, a psychedelic compound found in certain mushrooms, is being explored as a potential treatment for depression.

silocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effects, promoting neuroplasticity and reorganising functional connectivity across cortical and subcortical networks involved in emotion and cognition. Veterans with traumatic brain injuries (TBI) often experience chronic neurological and psychological symptoms such as post-traumatic stress disorder (PTSD) and depression. This study investigates the

Psychedelic drugs that activate 5-HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti-inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune responses, including inhibiting pro-inflammatory cytokine release.

Psilocybin, a natural compound found in certain mushrooms, has shown promise in treating depression and anxiety. UC San Francisco researchers wanted to know if it could be used to help Parkinson’s patients who often experience debilitating mood dysfunction in addition to their motor symptoms and don’t respond well to antidepressants or other medications. The results were surprising.

Research at The Florey suggests the psychedelic compound psilocybin has potential to treat obsessive-compulsive disorder (OCD) and related disorders. The study – led by Florey PhD student James Gattuso and supervised by Dr Thibault Renoir and Professor Anthony Hannan – found a single injected dose of psilocybin may reduce compulsive behaviours in mice.

Diabetes mellitus is a persistent metabolic disorder wherein the body struggles to adequately manage its blood glucose levels. This results from insufficient insulin production or reduced responsiveness to insulin. Consequently, individuals with diabetes experience elevated blood glucose levels, disrupting the metabolism of carbohydrates, proteins, and fats.